| 42.13 5.95 (16.45%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 51.99 |
1-year : | 60.73 |
| Resists | First : | 44.52 |
Second : | 51.99 |
| Pivot price | 26.77 |
|||
| Supports | First : | 28.95 |
Second : | 19.32 |
| MAs | MA(5) : | 32.77 |
MA(20) : | 25.98 |
| MA(100) : | 20.9 |
MA(250) : | 15.17 |
|
| MACD | MACD : | 3.2 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 86 |
D(3) : | 82.9 |
| RSI | RSI(14): 86.8 |
|||
| 52-week | High : | 44.52 | Low : | 6.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DFTX ] has closed above the upper band by 14.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 528.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 44.57 - 44.75 | 44.75 - 44.9 |
| Low: | 38.81 - 39.01 | 39.01 - 39.18 |
| Close: | 41.77 - 42.11 | 42.11 - 42.4 |
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Thu, 19 Feb 2026
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - Business Wire
Mon, 02 Feb 2026
Definium Therapeutics, Inc. Trade Ideas — NASDAQ:DFTX - TradingView
Mon, 26 Jan 2026
DFTX Stock Price and Chart — NASDAQ:DFTX - TradingView
Fri, 16 Jan 2026
MindMed stock soars 73% after InvestingPro’s undervalued call in May 2024 By Investing.com - Investing.com
Tue, 13 Jan 2026
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com
Tue, 13 Jan 2026
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 109 (M) |
| Shares Float | 108 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 74.8 (%) |
| Shares Short | 9,430 (K) |
| Shares Short P.Month | 9,360 (K) |
| EPS | -2.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.8 % |
| Return on Equity (ttm) | -94.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -145 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -16.86 |
| PEG Ratio | 0 |
| Price to Book value | 15.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|